To assess telomerase as a cancer therapeutic target and determine adaptive mechanisms to telomerase inhibition, we modeled telomerase reactivation and subsequent extinction in T cell lymphomas arising in Atm À/À mice engineered with an inducible telomerase reverse transcriptase allele. Telomerase reactivation in the setting of telomere dysfunction enabled full malignant progression with alleviation of telomere dysfunction-induced checkpoints. These cancers possessed copy number alterations targeting key loci in human T cell lymphomagenesis. Upon telomerase extinction, tumor growth eventually slowed with reinstatement of telomere dysfunctioninduced checkpoints, yet growth subsequently resumed as tumors acquired alternative lengthening of telomeres (ALT) and aberrant transcriptional networks centering on mitochondrial biology and oxidative defense. ALT+ tumors acquired amplification/overexpression of PGC-1b, a master regulator of mitochondrial biogenesis and function, and they showed marked sensitivity to PGC-1b or SOD2 knockdown. Genetic modeling of telomerase extinction reveals vulnerabilities that motivate coincidental inhibition of mitochondrial maintenance and oxidative defense mechanisms to enhance antitelomerase cancer therapy.
SUMMARY
To assess telomerase as a cancer therapeutic target and determine adaptive mechanisms to telomerase inhibition, we modeled telomerase reactivation and subsequent extinction in T cell lymphomas arising in Atm À/À mice engineered with an inducible telomerase reverse transcriptase allele. Telomerase reactivation in the setting of telomere dysfunction enabled full malignant progression with alleviation of telomere dysfunction-induced checkpoints. These cancers possessed copy number alterations targeting key loci in human T cell lymphomagenesis. Upon telomerase extinction, tumor growth eventually slowed with reinstatement of telomere dysfunctioninduced checkpoints, yet growth subsequently resumed as tumors acquired alternative lengthening of telomeres (ALT) and aberrant transcriptional networks centering on mitochondrial biology and oxidative defense. ALT+ tumors acquired amplification/overexpression of PGC-1b, a master regulator of mitochondrial biogenesis and function, and they showed marked sensitivity to PGC-1b or SOD2 knockdown. Genetic modeling of telomerase extinction reveals vulnerabilities that motivate coincidental inhibition of mitochondrial maintenance and oxidative defense mechanisms to enhance antitelomerase cancer therapy.
INTRODUCTION
Telomeres are nucleoprotein complexes at chromosome ends that function to maintain chromosomal integrity. Genetic models have defined their critical roles in cancer (Artandi and DePinho, 2010) , aging, and degenerative diseases (Sahin and DePinho, 2010) . Telomeres are synthesized by telomerase consisting of a reverse transcriptase catalytic subunit (TERT) and an RNA template subunit (TERC) (Feng et al., 1995; Nakamura et al., 1997) . As normal or premalignant cells divide, the end-replication problem of conventional DNA polymerases, coupled with low or absent telomerase activity, results in loss of telomere sequences and eventual telomere uncapping, which activates cellular checkpoints similar to those provoked by DNA doublestranded-breaks (DSBs) (Harley and Sherwood, 1997) . Like classical DSBs, telomere dysfunction has been shown to induce p53 and associated cellular responses, such as senescence and/or apoptosis (Chin et al., 1999; d'Adda di Fagagna et al., 2003; Karlseder et al., 1999; Takai et al., 2003; van Steensel et al., 1998) . Upon mutational inactivation of p53, continued cell cycling and survival of cells with telomere dysfunction provide a procarcinogenic mutator mechanism characterized by translocations and regional amplifications and deletions (Artandi et al., 2000; Chin et al., 1999; O'Hagan et al., 2002) . At the same time, persistent telomere dysfunction and associated rampant chromosomal instability (even in p53 null cells) compromises cellular viability (Begus-Nahrmann et al., 2009; Chin et al., 1999) and constrains full malignant progression of such cancers (Artandi et al., 2000; Chang et al., 2003; Gonzá lez-Suá rez et al., 2000; Rudolph et al., 2001 ).
The occurrence of telomere erosion and importance of telomerase-mediated telomere maintenance in fully established cancers are evidenced by typically short telomeres relative to normal tissues and robust telomerase activity in most human cancers (Shay and Wright, 2006) . This profile of shorter telomeres and telomerase activity in cancer has motivated the clinical development of telomerase inhibitors including a 13-mer antisense oligonucleotide in a number of cancer types (Agrawal et al., 2012; Shay and Wright, 2006) . At present, uncertainty surrounds whether antitelomerase therapy will be hampered by the potential lag time needed for telomere erosion-associated tumor cell killing, and/or whether re-entry into telomere-based crisis will engender genomic instability that may allow for emergence of adaptive responses and resistance mechanisms, such as alternative lengthening of telomeres (ALT) mechanism which enables telomere maintenance via homologous recombination (Cesare and Reddel, 2010) . Notably, in mTERC À/À mice, p53
deficiency alleviates tumor suppression imparted by telomere dysfunction (Chin et al., 1999) and, in transformed cells with intact p53-dependent DNA damage checkpoint, there is activation of ALT (Chang et al., 2003) . The study of cancer pathogenesis and specific role of telomeres therein have been enabled by the use of genetically engineered mouse models of cancer, which provide an in vivo assessment of the complex adaptive responses to targeted cancer treatments. Here, we exploited the experimental merits of mice to model and study more precisely telomere crisis, telomerase reactivation and telomerase extinction in cancer development, progression and treatment in the in vivo setting. To that end, we engineered an inducible TERT knockin allele and studied telomere dynamics in mice mutant for Atm, which develop T cell lymphomas with high penetrance (Xu et al., 1996) . The Atm mutant model was selected to study telomerase activation and its extinction as this model retains a robust p53-mediated checkpoint response upon telomere uncapping which strongly suppresses emergent tumors (Qi et al., 2003; Wong et al., 2003) . Our study provides in vivo genetic evidence that telomerase reactivation facilitates the progression of spontaneous arising tumors experiencing telomere dysfunction and, conversely, that telomerase extinction in established cancers activates ALT and other adaptive mechanisms, illuminating potential therapeutic combinations.
RESULTS

Telomerase Reactivation Promotes Tumorigenesis by Stabilizing Telomeres and Alleviating Telomere Dysfunction-Induced Checkpoints
We generated mice harboring an Atm null allele (Xu et al., 1996) and a 4-Hydroxytamoxifen (4-OHT)-inducible Telomerase Reverse Transcriptase-Estrogen Receptor (TERT-ER T2 ) fusion knockin allele (Jaskelioff et al., 2011) . In the absence of 4-OHT, mice homozygous for TERT ER (designated TERT ER/ER ) are telomerase activity deficient and sustain same cytogenetic and cellular phenotypes of conventional TERT or TERC knockout model (Jaskelioff et al., 2011) . Upon 4-OHT treatment, TERT-ER protein activity can be restored to levels comparable to the native TERT protein (Jaskelioff et al., 2011 G 0 and G 1 mice developed T cell lymphomas at similar latencies and penetrance ( Figure S1B ), which is consistent with adequate telomere reserves to maintain capping in G 1 mice and avoid activated DNA damage checkpoints. In contrast, G 3-4 lymphomas emerge with a longer latency and lower penetrance relative to G 1 controls ( Figure 1A ), consistent with previous work (Maser et al., 2007; Qi et al., 2003; Wong et al., 2003) . Next, to test the impact of telomerase reactivation on lymphoma kinetics in this model, continuous-release 4-OHT tablets were implanted subcutaneously at 18 weeks, an age when lymphomas in Atm À/À mice with intact telomeres start to emerge. 4-OHT-treated G 3-4 mice developed overt lymphomas more rapidly and with higher penetrance than, not only vehicletreated G 3-4 mice, but also G 1 mice ( Figure 1A ). In contrast, there were no differences in tumor latency and penetrance in the 4-OHT-and vehicle-treated G 1 mice ( Figure 1A The capacity to regulate endogenous telomerase activity in vivo prompted serial analyses of malignant properties and cellular checkpoint responses as functional readouts of telomere status during lymphomagenesis and progression in G 3-4 mice. Quantitation of DNA damage foci by anti-gH2AX and -53BP1 staining showed markedly increased foci in vehicle-treated G 3-4 tumor cells and a dramatic decrease in such foci in 4-OHT-treated G 3-4 tumor cells (Figures 2A and 2B ; Figure S2 ). Correspondingly, vehicle-treated G 3-4 tumor cells exhibited decreased proliferation (Ki67) and increased apoptosis (cleaved caspase 3), senescence (SA-b-Gal), and p53 signaling (p53 phosphorylation and p21 expression), which are all alleviated by telomerase reactivation (Figures 2C-2F ).
Telomerase Reactivation in Spontaneous Tumors with Unstable Genomes Promotes Aggressive Malignant Properties A higher percentage of G 3-4 -4-OHT mice exhibited widespread tumor cell infiltration in spleen, kidney, liver, lung, and bone marrow relative to vehicle-treated G 3-4 mice as well as 4-OHTand vehicle-treated G 1 mice ( Figures 3A and 3B ). The more aggressive nature of 4-OHT-treated G 3-4 lymphomas was particularly evident from infiltration into brain (4/16) which was not observed in G 1 necropsies (n = 16) ( Figures 3A and 3B ), demonstrating that the malignant progression of initiated tumors is enabled by somatic reactivation of telomerase. This acquisition of more aggressive tendencies may stem in part from increased genome instability during the formative stages of tumor development prior to telomerase activation. Indeed, telomere dysfunction-induced bridge-fusion-breakage events can generate non-reciprocal translocations as well as regional amplifications and deletions at sites of breakage that, under biological selection, can result in cancer-promoting copy number changes (Artandi et al., 2000; Maser et al., 2007; O'Hagan et al., 2002) . To examine this possibility, we compared cytogenetic and genomic profiles of 4-OHT-treated G 3-4 tumors and 4-OHT-treated G 1 tumors, the latter without a period of telomere-driven crisis. Consistent with previous work (Maser et al., 2007) , spectral karyotype (SKY) analysis showed a 3-fold increase in chromosomal rearrangements including nonreciprocal translocations in 4-OHT-treated G 3-4 tumors (n = 3) relative to 4-OHT-treated G 1 tumors (n = 3) ( Figures 3C and 3D , 25.8 versus 8.8 total NRTs per metaphase, respectively; p < 0.0001). The baseline of 8.8 NRTs per metaphase is consistent with previous work that ATM deficient tumors experience increased DNA doublestranded breaks, which promote chromosomal rearrangements as well (Xu et al., 1996) .
Examination of copy number alterations (CNAs) in 18 G 3-4 -4-OHT, 10 G 1 -4-OHT, and 5 G 3-4 -VEH tumors ( Figure 3E ; Figures S3A and S3B) revealed novel copy number gains on chromosomes 12, 17, and 18 and copy number losses on chromosome 14 in G 3-4 -4-OHT tumors but not G 1 -4-OHT tumors, consistent with increased genomic instability in late-generation tumors (Figure 3E ; Figure S3A ). Notably, G 3-4 -4-OHT and G 3-4 -VEH tumors show comparable levels of clonal CNAs, consistent with the view that wholesale genomic events driving lymphomagenesis occurs early in cancer development and that telomerase reactivation does not discernibly alter the scope of clonal genomic events in these cancers ( Figure 3E ; Figure S3B ). Along these lines, we assessed whether the observed CNAs in G 3-4 -4-OHT mice might contribute to the lymphomagenesis by examining whether murine and human lymphomas sustain orthologous CNA events than might be expected by chance as conducted previously (Maser et al., 2007) . Array-CGH profiles of G 3-4 -4-OHT tumors identified 4,928 genes resident within regions of genomic gain and 2,297 genes resident within regions of genomic loss with the use of Segment Gain or Loss (SGOL) algorithm (Wiedemeyer et al., 2010; Extended Experimental Procedures) . Comparison of G 3-4 -4-OHT tumors to human T-ALLs (Maser et al., 2007) showed that 565 of 4,928 amplified genes (11.5%) and 300 of 2,297 deleted genes (13%) are targeted for copy number alteration in both species (Table S1 ), which are significantly higher than those expected by chance (n = 10,000; p = 3e-04 and 2e-04 for amplification and deletion, respectively) ( Figure S3C ). These cross-species shared copy number altered genes include several known tumor suppressors and oncogenes implicated in T-ALL biology such as Crebbp, Ikaros, Abl, Notch1, Myc, and PTEN ( Figure 3E ). These data and previous work (Maser et al., 2007; O'Hagan et al., 2002) suggest that telomere dysfunction provides a mechanism that promotes structural genome alterations of cancer-relevant loci, which not only drive primary tumorigenesis but also confer additional malignant properties such as enhanced invasiveness.
Genetic Extinction of Telomerase Inhibits Cancer Growth and Leads to Eventual Tumor Re-Emergence
The TERT-ER system affords exploration of the impact of genetic extinction of telomerase activity in established cancers that, similar to human cancers, had evolved to first experience telomere dysfunction, and then subsequently acquire telomerase activity. In particular, this genetic model system enables assessment of tumor biological impact and potential adaptive mechanisms of antitelomerase therapy following reacquisition of telomere dysfunction. Freshly harvested 4-OHT-treated G 3-4 tumor cells mice were passaged directly through SCID mice preimplanted with vehicle or 4-OHT tablets ( Figure S4A ). Of 15 primary tumors lines (ten mice per each passage of treatment; 10 7 cells per intraperitoneal injection), 11 lines generated xenograft tumors. In first and second passages (P 1 and P 2 ), these lines showed no differences in the two treatment arms in terms of penetrance and latency ( Figure 4A ; P 1 and P 2 ). However, at third passage (P 3 ), 9 of 11 lines showed lower penetrance and longer latency in the vehicle-treated arm relative to the 4-OHTtreated arm, a profile consistent with the view that multiple rounds of cell division are needed to achieve sufficient telomere erosion and re-entry into crisis. Six of these nine lines showed complete loss of tumor formation in the vehicle-treated arm, whereas three lines yielded escaping tumors in several vehicletreated recipient mice ( Figure 4A ; P 3 ). When these escaping P 3 tumors were passaged to P 4 , they reacquired aggressive malignant properties approaching those of matched 4-OHT controls ( Figure 4A ; P 4 ), suggesting acquisition of resistant mechanisms to counteract telomerase deficiency. Moreover, 2 of the original 11 tumor lines did not show any attenuation of tumor growth in the vehicle-treated arm compared with the 4-OHT-treated arm (data not shown), suggesting early acquisition of such resistant mechanisms (see below).
To assess how G 3-4 -4-OHT tumors respond to telomerase extinction on molecular level, we audited p53 signaling, DNA damage foci and apoptosis in serial passages of the two treatment arms. In 4-OHT-treated P 1 to P 4 and vehicle-treated P 1 tumor cells, p53 signaling, DNA damage foci and apoptosis levels were similar to those of parental tumor cells 3), amplifications (bright red, log 2 R 0.6), losses (green, log 2 % À0.3), and deletions (dark green, log 2 % À0.6) for each locus is depicted. Locations of physiologically relevant CNAs of TCR loci and some known cancer genes are indicated with asterisks. See also Figure S3 and Table S1 .
(P 0 ) ( Figures 4B-4E ). In contrast, vehicle-treated P 2 tumor cells showed significantly higher levels of p53 signaling, DNA damage foci and apoptosis, and all of these processes were reduced in the resistant vehicle-treated P 3-4 tumor cells ( Figures 4B-4E ), raising the possibility that these resistant tumors may have stabilized their telomeres to alleviate these checkpoints. Intriguingly, while DNA damage foci were reduced in the resistant tumors compared with the vehicle-treated P 2 tumors, these foci remain higher than telomerase+ (4-OHT-treated) tumors (Figures 4D and 4E) , consistent with residual genotoxic stress in the resistant tumors. However, despite ongoing DNA damage signaling, apoptosis was not observed, which is consistent with compromised p53 signaling in the resistant tumors ( Figure S4B ).
Emergence of ALT in Tumors following Extinction of Telomerase
To elucidate adaptive mechanisms following telomerase extinction, we cataloged telomere lengths in serially passaged tumors in the two treatment arms. In passaged 4-OHT-treated P 1 to P 4 tumor cells, telomere lengths remained unchanged from those in parental tumor cells, while vehicle-treated P 1 and P 2 tumor cells showed progressive telomere shortening ( Figure 5A ). However, vehicle-treated P 3-4 tumor cells showed a sharp increase in average and maximal telomere lengths that exceeded those in matched 4-OHT controls ( Figure 5A) ; however, these vehicle-treated P 3-4 tumor cells tumor cells showed more telomere signal-free ends by telomere-FISH ( Figures 5B and 5C ), a picture consistent with higher heterogeneity in the distribution of telomere lengths in resistant tumors. In addition, costaining of promyelocytic leukemia (PML) bodies and telomeres showed an increase in ALT-associated PML bodies (APBs) (Figures 5D and   5E ), and telomere-FISH showed more extrachromosomal telomere fragments in the vehicle-treated P 3-4 tumors cells relative to the matched 4-OHT controls ( Figures 5F and 5G ). Finally, vehicle-treated P 3-4 tumor cells showed an increased telomere Sister Chromatid Exchange (tSCE) rate than matched 4-OHT controls ( Figures 5H and 5I ). These collective data provide clear evidence of ALT in vehicle-treated P 3-4 tumor cells that have resumed robust tumor growth in vivo. In addition, the two tumor lines, which did not show any attenuation of tumor growth in the vehicle-treated arm, also showed ALT features including APBs and extra-chromosomal telomere fragments (Figures S5A and S5B) , consistent with the early acquisition of ALT.
ALT Tumors Show Upregulation of a Master Regulator of Mitochondrial Biogenesis/Function and Oxidative Defense
Serial loss of telomere function and genome destabilization in this genetically defined system provided an unprecedented opportunity to discern on a genome scale the associated adaptive molecular events in these ALT+ tumor cells via integrated transcriptomic and aCGH profile analyses. Cluster analysis of transcriptomes of 4-OHT-treated P 4 tumors (n = 3), and parental 4-OHT-treated tumor revealed no significant differences (Figure 6A) , consistent with genomic stability brought about by continuous telomerase activity. In contrast, vehicle-treated ALT+ P 4 tumor (n = 5) expression profiles showed significant differences relative to the 4-OHT-treated telomerase-positive P 4 tumors, 891 upregulated and 1,345 downregulated genes in ALT+ tumors with 1.5-fold change and p < 0.01 (t test; Figure 6A ; Table S2 ). Pathway (IPA) analysis of the ALT-specific transcriptome showed strong representation of networks centering on 
test). (E) Quantification of g-H2AX foci positive cells in serially transplanted lymphomas treated with 4OHT or vehicle (n = 3-5, t test).
Error bars indicate SD (*p < 0.01 relative to any other individual samples in the same group). See also Figure S4 .
mitochondrial biology and oxidative stress regulation (Figure S6A) . Consistent with the known role of DNA recombination in ALT (Fan et al., 2009; Zhong et al., 2007) , MRE11 and FANCA were also upregulated in these ALT+ tumors ( Figures S6B and  S6C ). With regard to mitochondria and oxidative pathways, Q-PCR verified aberrant expression of several key genes in these networks including upregulation of a master regulator of mitochondrial biology and oxidative defense, PGC-1b, and its targets such as NRF2, SOD2, and Catalase, among others ( Figure 6B ). As noted, telomere dysfunction-induced DNA double-strand breakage process and biological selection can lead to functionally relevant CNAs, prompting us to identify potential genetic events that may inform how ALT+ cells cope with telomerebased crisis. To that end, we performed array-based comparative genomic hybridization (aCGH) analysis of ALT+ versus telomerase+ P 4 tumors from the two treatment arms. While serially transplanted telomerase+ tumors showed minimal CNA differences relative to the parental tumor, ALT+ tumors acquired numerous CNAs (see below). Strikingly, integrated transcriptomic and copy number analysis revealed PGC-1b as the only gene in the mitochondrial function and oxidative stress regulation pathways showing both upregulated expression and copy number gain in the ALT+ tumors relative to telomerase+ tumors (Table S3) ; these genomic data raised the possibility that PGC1b might be a major driver of the adaptive response to telomere dysfunction.
To ask whether PGC-1b amplification/overexpression is a common event in our ALT+ tumors, we profiled eight independent telomerase+ tumors and five independent ALT+ tumors, and found that three of five ALT+ tumors (60%) show amplification of a large region of chromosome 18, which includes PGC-1b gene, whereas none of the telomerase+ tumors (n = 8) sustain such genomic alterations ( Figure 6C ). To reinforce the potential role of PGC-1b upregulation as a possible adaptive response to ALT, we examined PGC-1b expression levels in ALT+ tumors without PGC-1b amplification, and established that PGC-1b expression is significantly higher in ALT+ tumors than their corresponding telomerase+ tumors ( Figure S6D ).
ALT+ Tumors Have Higher Levels of Mitochondrial Dysfunction and Reactive Oxygen Species Relative to Telomerase+ Tumors
PGC-1a and PGC-1b are master regulators of mitochondrial biogenesis and function, play integral roles in the regulation of genes governing reactive oxygen species (ROS) defense, and are downregulated in normal tissues experiencing telomere dysfunction as a result of activated p53-mediated repression . This framework, coupled with above genomic observations, prompted us to hypothesize that telomerase extinction and ensuing telomere dysfunction repress the mitochondrial biogenesis and function in cancer cells, and the adaptive response to such telomere-based crises targets the p53-PGC axis in an effort to restore the mitochondrial function. To assess this possibility, we assessed PGC network expression, mitochondrial mass and mitochondrial function in passaged 4-OHT-treated and vehicle-treated P 1 -P 4 tumor cells. Mitochondria DNA content were maintained in the telomerase+ arm but sharply reduced in the vehicle-treated P 2 tumor cells yet significantly restored in the ALT+ P 3-4 tumor cells ( Figure 6D ). Correspondingly, in contrast to the telomerase+ arm or early passage of vehicle-treated tumor cells, vehicle-treated P 2 tumor cells showed reduced expression of PGC-1b and its major targets NRF-1, ERRa, PPARa, and TFAM which are critical for mitochondrial biogenesis and function ( Figure 6E ; note: PGC1a is not expressed in these murine T cell lymphomas). These expression patterns were significantly normalized in the ALT+ P 3-4 tumor cells ( Figure 6E) .
With regard to mitochondrial function, mitochondrial respiration assays (normalized for mtDNA content) showed that vehicle-treated P 2 tumor cells have dramatically impaired mitochondrial respiration relative to telomerase+ cells ( Figure 6F ). ALT+ P 3-4 tumor cells show substantial improvement in mitochondrial respiration, although function remains somewhat compromised relative to those of telomerase+ cells ( Figure 6F ; Figure S6E ). Finally, the capacity of PGC-1b to regulate oxidative defense genes (St-Pierre et al., 2006) and the integral role of mitochondria in ROS control (Murphy, 2009 ) prompted examination of intracellular ROS levels in ALT+ and telomerase+ tumor cells. Using the fluorescent dye DCF-DA protocol, FACS analysis showed significantly increased ROS levels in vehicle-treated P 2 tumor cells relative to 4-OHT-treated P 0 to P 4 and vehicletreated P 1 tumor cells ( Figure 6G ; Figure S6F ). In ALT+ tumor cells, ROS levels are lower than vehicle-treated P 2 tumor cells, albeit higher than telomerase+ tumor cell controls ( Figure 6G ; Figure S6F ). Thus, telomere dysfunction in cancer cells is commonly associated with repression of PGC1b and its network resulting in mitochondrial mass decline and the adaptive responses to telomere dysfunction appear to involve not only activation of ALT telomere maintenance mechanism but also upregulation of genetic pathways promoting partial restoration of mitochondrial mass and function. Importantly, however, relative to telomerase+ cells, ALT+ tumor cells still have modestly elevated mitochondrial dysfunction and ROS which may reflect ongoing genotoxic stress relating to inefficiencies of telomere maintenance via ALT as reflected by moderately increased DNA damage foci above baseline in these tumors (see Figures  4D and 4E above) .
ALT+ Tumors Show Increased Sensitivity to Inhibition of PGC-1b or SOD2
Because relatively functional mitochondria and moderate levels of ROS are required for cancer cell survival (Weinberg et al., 2010) , we asked whether shRNA-mediated knockdown of PGC-1b would have a negative or differential impact on telomerase+ and ALT+ tumor cells. Multiple independent shRNAs achieved PGC-1b knockdown in both telomerase+ and ALT+ tumor cells ( Figure 7A ). Consistent with the pivotal role of PGC coactivators in mitochondrial function and ROS regulation, both telomerase+ and ALT+ tumor cells showed significantly reduced mitochondrial numbers, compromised mitochondrial function, and increased ROS after PGC-1b knockdown (Figures 7B-7D) . Notably, ALT+ tumor cells showed greater compromise in all three categories relative to telomerase+ tumor cells ( Figures 7B-7D ), raising the possibility that ALT+ tumor cells may show greater sensitivity to PGC-1b inhibition with increased mitochondrial dysfunction and ROS toxicity. Correspondingly, shRNA-mediated knockdown of PGC-1b showed a minimal impact on telomerase+ tumor growth and a profound impact on ALT+ cells ( Figure 7E ; median survival from 15 weeks to 19 weeks versus 17 weeks to over 30 weeks; p = 0.0065, Cox model). These findings are consistent with increased apoptosis in ALT+ tumors with PGC-1b knockdown ( Figure S7A ). In addition, since SOD2 is a major ROS antioxidant in mitochondria, regulated by PGC-1b, and highly expressed in ALT+ cells (Figure 6B) , we tested the impact of SOD2 knockdown in ALT+ and telomerase+ cells. As expected, SOD2 knockdown increased ROS levels in both telomerase+ and ALT+ cells, although ROS levels in ALT+ cells (both basal or after SOD2 knockdown) were substantially higher than those in telomerase+ cells ( Figures 7F and 7G) . On the biological level, while non-targeting shRNA-transduced telomerase+ and ALT+ cells showed similar cell survival rates (MTT assay), SOD2 knockdown in ALT+ cell decreased survival greater than in telomerase+ cells ( Figure 7H ; p = 0.02), suggesting that ALT+ cells are more sensitive to increase of ROS than telomerase+ cells. The sensitivity of ALT+ cells to ROS was further confirmed by NAC rescue experiments on ALT+ cells with PGC-1b and SOD2 knockdown ( Figures S7B and S7C) . Together, these data suggest that targeting PGC or ROS detoxifying genes may enhance the therapeutic impact of antitelomerase therapy, particularly in the context of ALT+-resistant cells.
DISCUSSION
One of the hallmarks of cancer cells is the shift from mitochondrial to glycolytic metabolism as the prime source of energy (E) RT-qPCR validation of mitochondrial biogenesis genes in serially transplanted lymphomas and ALT+ lymphomas (n = 3, t test).
(F) Oxygen Consumption Rates (OCRs) relative to mtDNA contents were measured in serially transplanted lymphomas and ALT+ lymphomas (n = 3, t test).
(G) ROS levels of serially transplanted lymphomas and ALT+ lymphomas were measured by DCFDA staining (n = 3-5, t test).
Error bars indicate SD (*p < 0.001, **p < 0.01 relative to any other individual samples in the same group). See also Figure S6 and Tables S2 and S3. and anabolic support (Vander Heiden et al., 2009; Warburg, 1956) . While this bioenergetic shift conveys decreased reliance on mitochondria as a major energy source for cancer cells, our genetic studies indicate a continued vital role in the maintenance of mitochondrial function in cancer. This view aligns with multiple lines of evidence suggesting that mitochondrial competence is indeed important for cancer cell viability (Jose et al., 2011; Koppenol et al., 2011) and efficient oncogene-mediated transformation (Gao et al., 2009; Weinberg et al., 2010; Wise et al., 2008; Yuneva et al., 2007) . More specifically, our study uncovers a critical role of robust mitochondrial function in cancer cells, particularly for those cancer cells with ALT-maintained telomeres. Why might ALT+ cancer cells exhibit exquisite sensitivity to inhibition of PGC expression or antioxidant defense? We speculate that continued DNA damage signaling at ALT-maintained telomeres perhaps due to altered chromatin (Heaphy et al., 2011) or inefficient capping via this mechanism could lead to mitochondrial damage. Mitochondria are the major intracellular source of ROS in mammalian cells, and dysfunctional mitochondria produce more ROS, which at excessively high levels is known to be detrimental to cell survival (Lin and Beal, 2006; Murphy, 2009; St-Pierre et al., 2006) . In this context, we propose that the pressure to maintain mitochondrial function reflects the need to maintain tolerable intracellular ROS levels. This oxidative defense mechanism may be particularly important for telomeres as ROS are particularly injurious toward the G-rich sequences of telomeres (Hall et al., 1996; Oexle and Zwirner, 1997; Retè l et al., 1993) , thereby causing increased telomere dysfunction in the absence of efficient telomerase-mediated repair. Correspondingly, our combined genomic and functional studies establish that ALT+ cells strive to maintain adequate mitochondrial and oxidative defense functions and show exquisite sensitivity to loss of such function. On the molecular level, this work also establishes that the intimate PGC-directed link between telomeres and mitochondria identified recently in normal tissues ) is operative in cancer cells ( Figure 7I ).
About 15% of human cancers maintain their telomeres in the absence of telomerase activity by the ALT mechanism. The existence of a telomerase-independent telomere maintenance mechanism was first identified in yeast with telomerase deficiency, and this mechanism was demonstrated to be dependent on RAD52, a gene involved in homologous recombination (Lundblad and Blackburn, 1993) . Subsequent studies established that the ALT mechanism in human cancer cells requires certain DNA recombination proteins, including the MRN complex (MRE11, RAD50, and NBS1) (Jiang et al., 2005; Zhong et al., 2007) , SMC5-SMC6 complex (Potts and Yu, 2007) , flap endonuclease 1 (FEN1) (Saharia and Stewart, 2009 ), MUS81 (Zeng et al., 2009) , Fanconi anemia group D2 (FANCD2), and Fanconi anemia group A (FANCA) (Fan et al., 2009 ). In our model, MRE11 and FANCA genes are indeed upregulated in ALT+ cells relative to telomerase+ cells ( Figures S4B and S4C ). These observations provide genetic evidence in mammalian cells of the importance of these factors for DNA recombination-dependent ALT mechanism in this cancer model.
Our studies also highlight that, while ALT+ cells suppress apoptosis and senescence as efficiently as telomerase+ cells, these cells do not fully restore mitochondrial function which we speculate may relate to ongoing genotoxic stress partly associated with less efficient telomere capping by ALT-mediated telomere maintenance (Cesare et al., 2009 ) as well as p53-independent repression of PGC . In ALT+ cells, the importance of this mitochondrial maintenance program is underscored by the upregulated PGC network signaling on both the genomic (copy number) and transcriptional levels ( Figure 7I ). That the PGC network is a vital regulator in our ALT+-resistant tumors is further substantiated by our analysis of published transcriptomic data comparing human ALT+ with telomerase+ osteosarcomas (Lafferty-Whyte et al., 2009) . Specifically, comparison of three key network genes (PGC-1a, NRF2, and SOD2; PGC-1b data is not available in this data set) in ten ALT+ and eight telomerase+ osteosarcomas showed that five of ten ALT+ osteosarcomas have significantly higher levels of one or multiple of PGC-1a, NRF2, and SOD2 genes relative to the basal levels, which is more prominent than telomerase+ tumors ( Figure S6G ) (p = 0.04), suggesting that upregulation of mitochondrial function and ROS defense pathway genes is important in other ALT+ cancer types. Thus, our genetic modeling of telomerase extinction in cancer increases our understanding of how tumor cells might respond and adapt to telomerase inhibition and illuminates a clinical path hypothesis utilizing combination regimens targeting telomerase and PGCmediated adaptive mechanisms in cancer.
EXPERIMENTAL PROCEDURES Mice
Atm, Terc, and TERT-ER mice described previously (Jaskelioff et al., 2011; Maser et al., 2007; Wong et al., 2003) were interbred and backcrossed to high grade of C57BL/6 (over 95%). The mating strategy to obtain experimental cohorts G 0 , G 1 , and G 3-4 is shown in Figure S1A . 4-OHT time release pellets (5 mg; Innovative Research of America) were inserted subcutaneously at age of 18 weeks to reach steady-state blood levels of 1 ng ml -1 4-OHT for 60 consecutive days.
Histology, Tumor Characterization, and Sample Preparation Antibodies used for IHC include anti-Ki67 (Dako), anti-53BP1 (Bethyl Labs), anti-gH2AX (Bethyl Labs), and anti-Cleaved Caspase 3 (Cell Signaling). For FACS analysis, cells were immunostained with CD4, CD8, and CD3 antibodies (eBioscience) and analyzed on a BD FACSCanto II (BD Biosciences).
Cytogenetic Analysis
For metaphase preparation, metaphases were obtained from colcemidtreated cells incubated in 105 mM KCl hypotonic buffer for 15 min before fixation in 3:1 methanol-acetic acid. Spectral karyotyping (SKY) was done using the SkyPaint Kit and SkyView analytical software (Applied Spectral Imaging) according to manufacturer's protocols. For telomere-FISH (fluorescent in situ hybridization), metaphase spreads were applied with telomere-specific T 2 AG 3 -FITC PNA (peptide nucleic acid) probes and centromere-specific Cent-Cy3 or Cent-pacific blue PNA probes, and counter-stained with DAPI (for microscopy) or TOTO3 (for laser scanning). Laser scanning cytometry quantification was performed with an iCys Research Imaging Cytometer (Compucyte) as described earlier (Jaskelioff et al., 2011; Sahin et al., 2011) .
Telomere Sister Chromatid Exchange Assay
Telomere Co-FISH staining was performed as previously described (Potts and Yu, 2007) . Details are described in Extended Experimental Procedures.
RT-qPCR, Mitochondria DNA Content Measurement, and Western Blot RT-qPCR primers are described in Table S4 . Mitochondrial DNA content was measured by the relative levels of CoxI versus beta globin by qPCR. CoxI and beta globin primers are described in Table S4 . Antibodies used for Western blotting are anti-phospho p53 (ser15, Cell Signaling), anti-p21 (Santa Cruz Biotechnology), anti-Vinculin (Sigma), and anti-Mre11 (BD Biosciences).
shRNA Knockdown Lentiviral based shRNA constructs targeting mouse PGC-1b and SOD2 were ordered from The Dana-Farber/Harvard Cancer Center DNA Resource Core. Verified shRNA sequences were cloned into inducible lentiviral constructs PLKO-TRC-901 (IPTG inducible; Broad Institute) and PLKO-Tet (Doxycycline inducible; Novartis).
Pathway Analysis
Eight hundred ninety-one upregulated and 1,345 downregulated genes with 1.5-fold change and p < 0.01 in ALT+ tumors relative to telomerase+ tumors were applied with Knowledge-based Pathway (IPA) analysis. The significantly represented pathways were compared with the pathways obtained from the similar analysis on ten ALT+ and eight telomerase+ osteosarcomas (LaffertyWhyte et al., 2009) . Overlapped pathways are listed.
Array-CGH Profiling and Analyses
Array-CGH, SGOL score analysis, homologous mapping, and permutation analysis are described in Extended Experimental Procedures.
Mitochondrial Oxygen Consumption Measurements in Live Cells
Oxygen consumption rates (OCRs) were measured using the Seahorse XF24 instrument (Seahorse Biosciences). Basal mitochondrial respiration were measured at four time points, and respiration nonlinked to mitochondrial ATP synthesis were measured at four time points after adding 1 mM oligomycin. Nonmitochondrial OCRs were obtained by adding 5 mM antimycin A, and uncoupled respiration was obtained by adding 1 mM FCCP.
ROS Measurement
For determination of ROS levels, tumor cells were stained with 5 mM CM-H 2 DFCDA (Invitrogen) at 37 C for 30 min, followed by FACS analysis on a BD FACSCanto II (BD Biosciences).
COX Model Test
Effects of shPGC-1b knockdown on Tel+ and ALT+ cells were tested by Cox analysis. Details are described in Extended Experimental Procedures.
ACCESSION NUMBERS
Microarray (GSE35044) and aCGH (GSE35045) data were deposited in GEO (http://www.ncbi.nlm.nih.gov/geo/) under the accession numbers indicated.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven figures, and four tables and can be found with this article online at doi:10.1016/ j.cell.2011.12.028.
